Gemcitabine for Advanced Salivary Cancer: A Phase II Study
- Evaluate the response rate of patients with incurable salivary gland cancer treated
- Evaluate the time to progression and toxicity of this therapy in these patients.
OUTLINE: This is a multicenter study.
Patients receive gemcitabine IV for 30 minutes on days 1, 8, and 15 of each 28 day course.
Patients receive a minimum of 2 courses of treatment. Patients may continue treatment in the
absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months.
PROJECTED ACCRUAL: This study will accrue a total of 16-60 patients.
Primary Purpose: Treatment
Marshall R. Posner, MD
Dana-Farber Cancer Institute
United States: Federal Government
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute||Boston, Massachusetts 02115|